文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

患者自我报告的症状和临床医生的评分作为总体癌症生存的预测因素。

Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival.

机构信息

Quality of Life Department, European Organization for Research and Treatment of Cancer Headquarters, Brussels, Belgium.

出版信息

J Natl Cancer Inst. 2011 Dec 21;103(24):1851-8. doi: 10.1093/jnci/djr485. Epub 2011 Dec 7.


DOI:10.1093/jnci/djr485
PMID:22157640
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3243678/
Abstract

BACKGROUND: The National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) reporting system is widely used by clinicians to measure patient symptoms in clinical trials. The European Organization for Research and Treatment of Cancer's Quality of Life core questionnaire (EORTC QLQ-C30) enables cancer patients to rate their symptoms related to their quality of life. We examined the extent to which patient and clinician symptom scoring and their agreement could contribute to the estimation of overall survival among cancer patients. METHODS: We analyzed baseline data regarding six cancer symptoms (pain, fatigue, vomiting, nausea, diarrhea, and constipation) from a total of 2279 cancer patients from 14 closed EORTC randomized controlled trials. In each trial that was selected for retrospective pooled analysis, both clinician and patient symptom scoring were reported simultaneously at study entry. We assessed the extent of agreement between clinician vs patient symptom scoring using the Spearman and kappa correlation statistics. After adjusting for age, sex, performance status, cancer severity, and cancer site, we used Harrell concordance index (C-index) to compare the potential for clinician-reported and/or patient-reported symptom scores to improve the accuracy of Cox models to predict overall survival. All P values are from two-sided tests. RESULTS: Patient-reported scores for some symptoms, particularly fatigue, did differ from clinician-reported scores. For each of the six symptoms that we assessed at baseline, both clinician and patient scorings contributed independently and positively to the predictive accuracy of survival prognostication. Cox models of overall survival that considered both patient and clinician scores gained more predictive accuracy than models that considered clinician scores alone for each of four symptoms: fatigue (C-index = .67 with both patient and clinician data vs C-index = .63 with clinician data only; P <.001), vomiting (C-index = .64 vs .62; P = .01), nausea (C-index = .65 vs .62; P < .001), and constipation (C-index = .62 vs .61; P = .01). CONCLUSION: Patients provide a subjective measure of symptom severity that complements clinician scoring in predicting overall survival.

摘要

背景:美国国立癌症研究所的不良事件通用术语标准(NCI-CTCAE)报告系统被临床医生广泛用于临床试验中测量患者症状。欧洲癌症研究与治疗组织的生活质量核心问卷(EORTC QLQ-C30)使癌症患者能够对与生活质量相关的症状进行评分。我们研究了患者和临床医生症状评分及其一致性在多大程度上有助于估计癌症患者的总生存率。

方法:我们分析了来自 14 项 EORTC 随机对照试验的 2279 例癌症患者的 6 种癌症症状(疼痛、疲劳、呕吐、恶心、腹泻和便秘)的基线数据。在每个被选择进行回顾性汇总分析的试验中,同时报告了临床医生和患者的症状评分。我们使用 Spearman 和 kappa 相关统计来评估临床医生与患者症状评分之间的一致性程度。在调整年龄、性别、表现状态、癌症严重程度和癌症部位后,我们使用 Harrell 一致性指数(C 指数)来比较临床医生报告和/或患者报告的症状评分对改善 Cox 模型预测总生存率的准确性的潜力。所有 P 值均来自双侧检验。

结果:患者对某些症状(尤其是疲劳)的评分与临床医生的评分不同。在我们评估的 6 种基线症状中,临床医生和患者的评分都独立且积极地提高了生存预后预测的准确性。对于我们评估的四个症状(疲劳、呕吐、恶心和便秘),考虑患者和临床医生评分的 Cox 总体生存模型比仅考虑临床医生评分的模型具有更高的预测准确性(C 指数:疲劳为 0.67(同时考虑患者和临床医生数据)与 0.63(仅考虑临床医生数据);P<0.001);呕吐为 0.64(同时考虑患者和临床医生数据)与 0.62(仅考虑临床医生数据);P=0.01);恶心为 0.65(同时考虑患者和临床医生数据)与 0.62(仅考虑临床医生数据);P<0.001);便秘为 0.62(同时考虑患者和临床医生数据)与 0.61(仅考虑临床医生数据);P=0.01)。

结论:患者提供了症状严重程度的主观衡量标准,与临床医生评分一起预测总生存率。

相似文献

[1]
Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival.

J Natl Cancer Inst. 2011-12-7

[2]
Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes.

J Natl Cancer Inst. 2009-12-2

[3]
The Added Value of Analyzing Pooled Health-Related Quality of Life Data: A Review of the EORTC PROBE Initiative.

J Natl Cancer Inst. 2015-12-28

[4]
Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials.

J Natl Cancer Inst. 2014-7-8

[5]
Predictive value of symptoms for ovarian cancer: comparison of symptoms reported by questionnaire, interview, and general practitioner notes.

J Natl Cancer Inst. 2012-1-13

[6]
Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials.

Lancet Oncol. 2009-9

[7]
Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials.

Support Care Cancer. 2010-8-6

[8]
A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites.

Cancer. 2013-10-11

[9]
The impact of radiotherapy on quality of life for cancer patients: a longitudinal study.

Support Care Cancer. 2014-9

[10]
Comparison of EORTC QLQ-C30 and PRO-CTCAE™ Questionnaires on Six Symptom Items.

J Pain Symptom Manage. 2018-5-25

引用本文的文献

[1]
Fatigue, physical function, and the context of social vulnerability for older adults with cancer.

J Geriatr Oncol. 2025-7

[2]
Yoga for fatigue in people with cancer.

Cochrane Database Syst Rev. 2025-5-27

[3]
Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study.

Future Oncol. 2025-5

[4]
PRO-Based Stratification Improves Model Prediction for Toxicity and Survival of Head and Neck Cancer Patients.

IEEE J Biomed Health Inform. 2025-2

[5]
Cardiovascular training for fatigue in people with cancer.

Cochrane Database Syst Rev. 2025-2-20

[6]
Relationships between patient-reported and clinician-rated toxicities and daily functioning in older adults with advanced cancer undergoing systemic therapy.

Cancer. 2025-2-15

[7]
Resistance training for fatigue in people with cancer.

Cochrane Database Syst Rev. 2024-11-28

[8]
Cardiovascular training versus resistance training for fatigue in people with cancer.

Cochrane Database Syst Rev. 2024-9-4

[9]
Efficacy and Safety Analysis of Transarterial Chemoembolization Plus Donafenib With or Without Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: A Prospective, Single-Arm, Single-Center, Phase II Clinical Study.

J Hepatocell Carcinoma. 2024-6-27

[10]
A study demonstrating users' preference for the adapted-REQUITE patient-reported outcome questionnaire over PRO-CTCAE in patients with lung cancer.

Front Oncol. 2024-4-10

本文引用的文献

[1]
Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials.

Support Care Cancer. 2010-8-6

[2]
Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes.

J Natl Cancer Inst. 2009-12-2

[3]
Patient symptoms and clinician toxicity ratings: both have a role in cancer care.

J Natl Cancer Inst. 2009-12-2

[4]
Other paradigms: health-related quality of life as a measure in cancer treatment: its importance and relevance.

Cancer J. 2009

[5]
Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials.

Lancet Oncol. 2009-9

[6]
The prognostic significance of patient-reported outcomes in cancer clinical trials.

J Clin Oncol. 2008-3-10

[7]
Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.

J Clin Oncol. 2007-12-20

[8]
Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study.

J Clin Oncol. 2007-12-20

[9]
Should patient-reported outcomes be mandatory for toxicity reporting in cancer clinical trials?

J Clin Oncol. 2007-12-1

[10]
Does QOL provide the same information as toxicity data?

Curr Probl Cancer. 2006

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索